At Allorion Therapeutics, we focus on developing novel small molecule drugs against cancer and autoimmune diseases. Our team is comprised of experts in cancer biology and drug development. The fields we want to dive into include:
• selecting well-validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of actions
• building our innovative data and screening platforms for sustainable success
• constructing chemical libraries with priorities on allosteric and covalent modulators and optimizing the libraries through the aid of AI
Allorion has dual sites operating in Natick, Massachusetts and Guangzhou, China.
• selecting well-validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of actions
• building our innovative data and screening platforms for sustainable success
• constructing chemical libraries with priorities on allosteric and covalent modulators and optimizing the libraries through the aid of AI
Allorion has dual sites operating in Natick, Massachusetts and Guangzhou, China.
Location: United States, Massachusetts, Natick
Employees: 11-50
Total raised: $90M
Founded date: 2020
Investors 3
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
| 27.04.2023 | INCE Capit... | incecap.co... |
| 17.01.2024 | Qiming Ven... | qimingvc.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.03.2023 | Series B | $50M | - |
| 24.11.2021 | Series A | $40M | - |
Mentions in press and media 10
| Date | Title | Description |
| 27.11.2025 | INCE Capital’s Portfolio Company Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs | Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), announced the completion of its oversubscribed Series A-2 f... |
| 17.03.2025 | Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases | Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, announced the successful completion of its oversubscribed Series A financing of approxima... |
| 02.01.2024 | Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca | NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has ... |
| 13.03.2023 | Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing | - |
| 11.03.2023 | USA and China-based Allorion Therapeutics raises USD 50 million in Series B | Boston, USA and Guangzhou, China-based biotech company focusing on medicine for oncology and autoimmune diseases, Allorion Therapeutics, raised USD 50 million in Series B. The round took place on March 9, 2023. Ince Capital and Qiming Ventu... |
| 10.03.2023 | Allorion Therapeutics Raises $50M in Series B Financing | Allorion Therapeutics, a Boston, MA- and Guangzhou, China-based biotech company focusing on medicine for oncology and autoimmune diseases, raised $50M in Series B funding. The round was led by Ince Capital and Qiming Venture Partners, with ... |
| 10.03.2023 | Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing | BOSTON, March 10, 2023 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a $50 million Series B f... |
| 10.03.2023 | China Digest: SVision Imaging, Allorion Therapeutics snap funds; Ziroom said to be planning $1b HK IPO | China Life Private Equity Investment co-leads SVision Imaging’s Series C round, while Qiming Venture Partners co-leads Allorion Therapeutics’s Series B round. Also, apartment rental platform Ziroom is reportedly considering a $1-billion Hon... |
| 24.11.2021 | Allorion Therapeutics Completes $40M Series A Financing Round | Allorion Therapeutics, a Boston, MA-based next-generation precision medicine company focused on oncology and autoimmune diseases, compled a $40M Series A financing. This round was led by Qiming Venture Partners with participation from IDG C... |
| - | Allorion Therapeutics | “Allorion Therapeutics” |